Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price objective increased by stock analysts at Robert W. Baird from $118.00 to $140.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price objective indicates a potential upside of 2.62% from the stock's current price.

Other equities research analysts also recently issued research reports about the company. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Mizuho cut their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the company from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Thursday. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $175.23.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $136.43 on Thursday. The company has a market cap of $6.70 billion, a P/E ratio of 909.55, a P/E/G ratio of 4.54 and a beta of 1.50. The firm's fifty day moving average price is $139.36 and its two-hundred day moving average price is $167.15. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same period in the prior year, the firm earned $2.27 EPS. The business's revenue was down 2.7% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. Rothschild Investment LLC lifted its holdings in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares during the last quarter. HM Payson & Co. bought a new position in Charles River Laboratories International in the 1st quarter worth approximately $31,000. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the 4th quarter valued at $37,000. Finally, GeoWealth Management LLC raised its holdings in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.